Pfizer Pays $135M To Bow Out Of Marketing Deal

Law360, New York (November 13, 2007, 12:00 AM EST) -- Pfizer Inc. seems to have mended its fraying relationship with partner Nektar Therapeutics by agreeing to pay Nektar $135 million in order to bow out of a marketing agreement the two companies had over the diabetes drug Exubera.

The companies announced Tuesday that they have resolved all contractual issues in relation to Exubera with the one-time payment of $135 million putting to rest any remaining obligations Pfizer had to Nektar.

“This agreement demonstrates the industry leadership of Pfizer and the company’s desire to work with world-class...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.